JP2019504105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504105A5 JP2019504105A5 JP2018540862A JP2018540862A JP2019504105A5 JP 2019504105 A5 JP2019504105 A5 JP 2019504105A5 JP 2018540862 A JP2018540862 A JP 2018540862A JP 2018540862 A JP2018540862 A JP 2018540862A JP 2019504105 A5 JP2019504105 A5 JP 2019504105A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor
- composition
- administration
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 7
- 210000004027 cells Anatomy 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 210000004556 Brain Anatomy 0.000 claims 2
- 208000005017 Glioblastoma Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 230000002601 intratumoral Effects 0.000 claims 2
- 210000004881 tumor cells Anatomy 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 210000000481 Breast Anatomy 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 210000003128 Head Anatomy 0.000 claims 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 210000003739 Neck Anatomy 0.000 claims 1
- 230000000735 allogeneic Effects 0.000 claims 1
- 201000005216 brain cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (18)
- 中枢神経系の悪性腫瘍と診断された患者を治療する方法であって、腫瘍細胞抗原を標的とする有効量のT細胞を含む組成物を前記患者に脳室内投与することを含み、ここで、前記T細胞は腫瘍細胞抗原に結合するキメラ抗原レセプターを発現する細胞を含む方法。
- 前記T細胞が自己又は同種異系T細胞である、請求項1に記載の方法。
- 前記投与が、左脳室(ventricle)又は右脳室(ventricle)への投与である、請求項1に記載の方法。
- 前記組成物が少なくとも1×106個の細胞を含む、請求項1に記載の方法。
- T細胞を含む前記組成物が少なくとも2回投与される、請求項1に記載の方法。
- 前記投与が、投与されたT細胞の総数が異なる、請求項5に記載の方法。
- 前記投与が用量を段階的に増大する、請求項5に記載の方法。
- 前記投与が用量を段階的に縮小する、請求項5に記載の方法。
- 前記悪性腫瘍が、びまん性の浸潤性腫瘍である、請求項1に記載の方法。
- 前記悪性腫瘍が原発性脳腫瘍である、請求項1に記載の方法。
- 1つ以上の腫瘍病巣のサイズが少なくとも25%減少する、請求項1に記載の方法。
- 前記悪性腫瘍が、乳癌、肺癌、頭頸部癌、及び黒色腫から選択される原発癌から生じる、請求項1に記載の方法。
- 当該方法が腫瘍切除後に行われる、請求項1に記載の方法。
- T細胞を含む組成物の腫瘍内投与をさらに含む、請求項1に記載の方法。
- 前記悪性腫瘍が続発性脳腫瘍である、請求項1に記載の方法。
- グリア芽細胞腫細胞の表面上に発現されるタンパク質に結合するキメラ抗原レセプターを発現する治療用T細胞を含む組成物の腫瘍内投与をさらに含む、請求項1に記載の方法。
- 前記悪性腫瘍がグリア芽細胞腫である、請求項1に記載の方法。
- 前記T細胞がIL−13レセプターに結合するキメラ抗原レセプターを発現する、請求項17に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022192529A JP2023026758A (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えt細胞の投与 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662292152P | 2016-02-05 | 2016-02-05 | |
US62/292,152 | 2016-02-05 | ||
US201662309348P | 2016-03-16 | 2016-03-16 | |
US62/309,348 | 2016-03-16 | ||
PCT/US2017/016711 WO2017136829A1 (en) | 2016-02-05 | 2017-02-06 | Administration of engineered t cells for treatment of cancers in the central nervous system |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022192529A Division JP2023026758A (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えt細胞の投与 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019504105A JP2019504105A (ja) | 2019-02-14 |
JP2019504105A5 true JP2019504105A5 (ja) | 2020-03-19 |
JP7189019B2 JP7189019B2 (ja) | 2022-12-13 |
Family
ID=59496551
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018540862A Active JP7189019B2 (ja) | 2016-02-05 | 2017-02-06 | 中枢神経系の癌の治療のための操作されたt細胞の投与 |
JP2022192529A Pending JP2023026758A (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えt細胞の投与 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022192529A Pending JP2023026758A (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えt細胞の投与 |
Country Status (15)
Country | Link |
---|---|
US (2) | US20170224733A1 (ja) |
EP (2) | EP3411393B1 (ja) |
JP (2) | JP7189019B2 (ja) |
KR (1) | KR20180105709A (ja) |
CN (1) | CN108779160A (ja) |
AU (2) | AU2017213661B2 (ja) |
BR (1) | BR112018015836A2 (ja) |
CA (1) | CA3013773A1 (ja) |
DK (1) | DK3411393T3 (ja) |
ES (1) | ES2879700T3 (ja) |
HK (1) | HK1257741A1 (ja) |
IL (2) | IL287889B2 (ja) |
MX (1) | MX2023006304A (ja) |
RU (1) | RU2757308C2 (ja) |
WO (1) | WO2017136829A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6788573B6 (ja) | 2014-04-10 | 2020-12-16 | シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート | メトトレキサートによる選択と組み合わせたSleeping Beautyトランスポゾンによる遺伝子改変T細胞の製造 |
AU2016306209B2 (en) | 2015-08-07 | 2023-07-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific CAR T-cells for solid tumor targeting |
EP3551197B1 (en) | 2016-12-12 | 2023-11-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
CN109971725B (zh) * | 2017-12-28 | 2024-02-02 | 上海细胞治疗研究院 | 抗体修饰的嵌合抗原受体修饰t细胞及其用途 |
CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院(Dba西雅图儿童研究所) | Car t细胞的使用方法 |
BR112020018534A2 (pt) * | 2018-03-14 | 2020-12-29 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Imunoterapia com células t direcionadas por zetacina alvejada por receptor alfa 2 da il-13 |
US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
EP3802579A1 (en) * | 2018-06-01 | 2021-04-14 | The Board of Trustees of the Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
EP4097127A2 (en) * | 2020-01-31 | 2022-12-07 | City of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES |
WO2021202793A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Chimeric antigen receptors targeting cd33 |
CN113646433B (zh) * | 2020-07-16 | 2022-10-11 | 苏州博腾生物制药有限公司 | 靶向抗TNF-α抗体的组合物和方法 |
WO2022012610A1 (en) * | 2020-07-16 | 2022-01-20 | Porton Biologics Ltd | Compositions and methods to target anti-tnf-alpha antibody |
WO2022109611A1 (en) | 2020-11-20 | 2022-05-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
JP2024514308A (ja) * | 2021-03-30 | 2024-04-01 | シティ・オブ・ホープ | CAR T細胞療法及びIFNγ |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514537B2 (en) * | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
WO2008121420A1 (en) * | 2007-03-30 | 2008-10-09 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
ES2961498T3 (es) * | 2008-08-26 | 2024-03-12 | Hope City | Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T |
US9181527B2 (en) * | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
WO2012066495A2 (en) * | 2010-11-17 | 2012-05-24 | Ben Gurion University Of The Negev Research And Development Authority | T-cell therapy to neurodegenerative diseases |
WO2014028925A1 (en) * | 2012-08-17 | 2014-02-20 | Memorial Sloan-Kettering Cancer Center | Gene expression profile associated with prostate cancer |
WO2014070957A1 (en) * | 2012-10-30 | 2014-05-08 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
JP6560235B2 (ja) * | 2014-01-13 | 2019-08-14 | シティ・オブ・ホープCity of Hope | Fcスペーサー領域に変異を有するキメラ抗原受容体(CAR)及びそれらの使用方法 |
CA2945388A1 (en) * | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
AU2016306209B2 (en) * | 2015-08-07 | 2023-07-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific CAR T-cells for solid tumor targeting |
CN105131126B (zh) * | 2015-10-10 | 2019-02-01 | 北京康爱瑞浩细胞技术有限公司 | 用于治疗恶性肿瘤的嵌合抗原受体及其制备方法与应用 |
BR112018009129A2 (pt) * | 2015-11-04 | 2019-02-26 | J. PRICEMAN Saul | receptores de antígeno quimérico que visam her2 |
-
2017
- 2017-02-06 CA CA3013773A patent/CA3013773A1/en active Pending
- 2017-02-06 IL IL287889A patent/IL287889B2/en unknown
- 2017-02-06 US US15/425,773 patent/US20170224733A1/en not_active Abandoned
- 2017-02-06 KR KR1020187025196A patent/KR20180105709A/ko not_active Application Discontinuation
- 2017-02-06 EP EP17748349.2A patent/EP3411393B1/en active Active
- 2017-02-06 BR BR112018015836A patent/BR112018015836A2/pt unknown
- 2017-02-06 CN CN201780017442.9A patent/CN108779160A/zh active Pending
- 2017-02-06 AU AU2017213661A patent/AU2017213661B2/en active Active
- 2017-02-06 ES ES17748349T patent/ES2879700T3/es active Active
- 2017-02-06 WO PCT/US2017/016711 patent/WO2017136829A1/en active Application Filing
- 2017-02-06 DK DK17748349.2T patent/DK3411393T3/da active
- 2017-02-06 JP JP2018540862A patent/JP7189019B2/ja active Active
- 2017-02-06 EP EP21166981.7A patent/EP3912993A1/en active Pending
- 2017-02-06 RU RU2018130752A patent/RU2757308C2/ru active
-
2018
- 2018-08-01 IL IL260930A patent/IL260930B/en unknown
- 2018-08-03 MX MX2023006304A patent/MX2023006304A/es unknown
-
2019
- 2019-01-04 HK HK19100115.9A patent/HK1257741A1/zh unknown
-
2020
- 2020-09-18 US US17/025,723 patent/US20210244761A1/en active Pending
-
2022
- 2022-09-02 AU AU2022224866A patent/AU2022224866A1/en active Pending
- 2022-12-01 JP JP2022192529A patent/JP2023026758A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019504105A5 (ja) | ||
Martin et al. | Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges | |
Pol et al. | Trial watch: oncolytic viruses for cancer therapy | |
MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
JP2018502120A5 (ja) | ||
JP2020510624A5 (ja) | ||
JP2016535009A5 (ja) | ||
Asna et al. | Radiation therapy and immunotherapy—a potential combination in cancer treatment | |
EA201490911A1 (ru) | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина | |
JP2016528162A5 (ja) | ||
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
WO2021182573A1 (ja) | 癌の治療及び/又は予防のための医薬品 | |
RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
Wu et al. | Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma | |
RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
Marcu | Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments | |
JP2016501234A5 (ja) | ||
MX2020001254A (es) | Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf. | |
Srivastava et al. | Tumor niches: perspectives for targeted therapies in glioblastoma | |
Sai et al. | Basic and translational research on carbon-ion radiobiology | |
Gutova et al. | Intranasal delivery of therapeutic neural stem cells to target intracerebral glioma | |
Kulchitsky et al. | Prospects of chemotherapy side effects minimization | |
WO2022020648A9 (en) | Inhibitors of the artemin pathway for treatment of cancer | |
EP4100030A1 (en) | Oncolytic virus compositions and methods for the treatment of cancer |